AP
PGNX

AHL Partners’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

AHL Partners’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-19,919
Closed -$147K – 1413
2017
Q3 		$147K Buy
+19,919
New +$127K ﹤0.01% 1212

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
PFC
Phocas Financial Corp Alameda, California $637M AUM 39.08% 1-Year Est. Return

AHL Partners's PGNX Position: Q4 2017 in Review

AHL Partners sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2017, closing a stake of 19,919 shares — an estimated $147K sold.

AHL Partners first reported a position in PGNX in Q3 2017 and held it in 1 quarter. The position peaked at $147K in Q3 2017. 153 funds tracked by Wall St. Rank hold PGNX as of Q4 2017.

  • AHL Partners reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
  • AHL Partners sold 19,919 Progenics Pharmaceuticals Inc shares in Q4 2017, an estimated $147K.
  • AHL Partners first reported a position in Progenics Pharmaceuticals Inc in Q3 2017 and held it in 1 quarter.
  • AHL Partners's Progenics Pharmaceuticals Inc position peaked at $147K in Q3 2017.
  • 153 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.